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Abstract Like ubiquitin (Ub), the ubiquitin-like protein
FAT10 can serve as a signal for proteasome-dependent
protein degradation. Here, we investigated the contribution
of FAT10 substrate modiﬁcation to MHC class I antigen
presentation. We show that N-terminal modiﬁcation of the
human cytomegalovirus-derived pp65 antigen to FAT10
facilitates direct presentation and dendritic cell-mediated
cross-presentation of the HLA-A2 restricted pp65495–503
epitope. Interestingly, our data indicate that the pp65 pre-
sentation initiated by either FAT10 or Ub partially relied
on the 19S proteasome subunit Rpn10 (S5a). However,
FAT10 distinguished itself from Ub in that it promoted a
pp65 response which was not inﬂuenced by immunopro-
teasomes or PA28. Further divergence occurred at the level
of Ub-binding proteins with NUB1 supporting the pp65
presentation arising from FAT10, while it exerted no effect
on that initiated by Ub. Collectively, our data establish
FAT10 modiﬁcation as a distinct and alternative signal for
facilitated MHC class I antigen presentation.
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Abbreviations
DUB De-ubiquitylating enzyme
FAT10 HLA-F adjacent transcript 10
NUB1 NEDD8 ultimate buster 1
PA28 Proteasome activator 28
pp65 Phosphoprotein 65
Ub Ubiquitin
UBL Ubiquitin-like modiﬁer
UPS Ubiquitin–proteasome system
Introduction
The production of minimal CD8? T cell antigenic peptides
mostly depends on the degradation of target proteins by the
ubiquitin–proteasome system (UPS). In this pathway,
covalently attached ubiquitin (Ub) typically marks a sub-
strate protein for degradation by the 26S proteasome, and it
has been shown that increased susceptibility to ubiquity-
lation can facilitate MHC class I antigen presentation in
vivo [1–3]. Conjugation of Ub to lysine (K) side chains of
target proteins uses the concerted actions of a succession of
speciﬁc enzymes (E1, E2 and E3) that sequentially transfer
the activated Ub to a protein substrate. K48-linked chains
are the most abundant forms of poly-Ub chains within the
cells and target substrates for 26S proteasome-mediated
degradation. The 26S proteasome complex consists of two
sub-complexes: the 19S regulatory particle and the 20S
particle containing the three catalytic subunits b1, b2 and
b5. In mammalian cells, upon induction by type I and/or II
interferon (IFN), these constitutive catalytic subunits are
replaced by the inducible subunits ib1/LMP2, ib2/MECL1
and ib5/LMP7, forming the immunoproteasome (i-protea-
some) [4–6]. Studies of i-proteasome function have revealed
that, in most instances, it generates MHC class I-binding
peptides more efﬁciently than standard proteasomes
(s-proteasomes)[7–9].IFN-cstimulationisalsoaccompanied
by increased expression of the proteasome activator PA28,
which associates with the 20S proteasome, thereby forming
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123so-calledhybridproteasomescomplexes(i.e.19S-20S-PA28)
that enhance the production of antigenic peptides [10, 11].
Over the past decade, a growing number of Ub-like pro-
teins (UBL) sharing structural homology with Ub have been
identiﬁed, such as NEDD8, SUMO, ISG15 and FAT10 [12,
13]. Like Ub, they exhibit the capacity to be conjugated to K
residues in a substrate protein, and are involved in the reg-
ulation of diverse cellular processes, including nuclear
transport, transcription, stress response, and DNA damage.
FAT10 (HLA-F-adjacent transcript 10) is the most recently
identiﬁed member of the UBL family and, up to now, very
little is known about its biological function. FAT10 gene
expression has been reported to be under the inﬂuence of
cytokines,includingTNF-aandIFN-c,andistimelyinduced
during the later phase of dendritic cell (DC) maturation and
during apoptosis [14–16]. Increased levels of both free
FAT10 and FAT10-protein conjugates have also been
reported in various tumours including hepatocellular carci-
noma as well as gastric and gynaecological cancers [17, 18].
Although the lymphocytes from FAT10
-/- mice were, on
average, more prone to spontaneous apoptotic death, no
histological differences were found between wild-type and
FAT10
-/- mice [19]. Within cells, FAT10 is covalently
conjugated to cellular proteins in a pathway involving an
E1-E2-E3 enzyme cascade, which is only partially charac-
terised. Recently, UBE1L2 and UBE2Z have been reported
to function as E1 and E2 enzymes for FAT10, respectively
[20,21],whereasnoFAT10-speciﬁcE3enzymeshavesofar
been experimentally veriﬁed.
Interestingly, FAT10 shares with Ub the unique ability
of targeting substrates for proteasomal degradation [15,
22]. However, there exists no information whether FAT10
modiﬁcation of a substrate protein may contribute to the
peptide supply for MHC class I-restricted antigen presen-
tation. Here, we show that an N-terminal fusion of the
human cytomegalovirus (HCMV)-derived pp65 antigen
with FAT10 accelerates the proteasomal degradation of
pp65 and results in improved presentation of the HLA-A2-
restricted pp65495–503 epitope. Importantly, the antigen
processing pathway used by this FAT10-pp65 fusion pro-
tein differs considerably from that used by an Ub-pp65
chimera in terms of i-proteasomes, PA28 and Ub-binding
proteins. In summary, our data underscore the importance
of the FAT10 conjugation system as an alternative and
distinct pathway for MHC class I antigen processing.
Materials and methods
Reagents and antibodies
Anti-pp65 (CH12), anti-FAT10 (FL-165) and anti-b-actin
(C4) antibodies were purchased from Santa Cruz
Biotechnology. Monoclonal anti-LMP2 (LMP2-13), anti-
Ub (FK2), anti-Rpn10 (S5a-18) and polyclonal anti-NUB1
antibodies were obtained from Biomol. The polyclonal
anti-PA28-b was purchased from Cell Signaling. Anti-HA
monoclonal antibody (16B12) was obtained from Covance.
Antibodies against PA28-a, MECL1 (K65/4) and LMP7
(K63/5) were from the laboratory stock and used as
previously described [23]. MG132 (benzyloxycarbonyl-
Leu-Leu-Leu-CHO), N-ethylmaleimide (NEM) and phy-
tohaemagglutinin (PHA-L) were all purchased from Sigma.
Lipopolysaccharide (LPS) was obtained from Invivogen.
Unless speciﬁed, all recombinant cytokines used in this
study (IL-2, TNF-a, IFN-c) were purchased from Miltenyi
Biotec. The peptide pp65495–503 (NLVPMVATV) was
custom-synthesised by our peptide synthesis facility
(Institute of Biochemistry, Charite ´, Berlin).
Cell culture
The stable cell line HeLa A2? (clone 33) was established
in our laboratory and cultivated in Iscove Medium sup-
plemented with 10% FCS in the presence of 2 lg/ml
puromycin. The expression of HLA-A2 molecules on the
cell surface was determined using ﬂow cytometry, using
the BB7.2 mAb (kindly provided by Dr. A. Paschen, Essen,
Germany). The clone 33/2 (HeLa A2?/IP) is a derivative
of the clone 33 that stably expresses the three inducible
subunits LMP2, MECL1 and MECL1 and was maintained
in the presence of 2 lg/ml puromycin and 300 lg/ml
hygromycin. HEK293 cells were grown in DMEM medium
(Biochrom, Berlin, Germany) containing 10% FCS, 2 mM
L-glutamine and 100 U/ml penicillin and streptomycin
(purchased from PAA Laboratories), as previously descri-
bed [24]. DC were generated from enriched CD14?
monocytes cultured in the presence of GM-CSF (500 U/ml)
and IL-4 (100 U/ml) for 5 days. The pp65 CTL clone
61, speciﬁc for pp65495–509, was generated from sensitisa-
tions of naı ¨ve CD8? T cells with peptide-pulsed DC, as
previously described [14]. It was regularly expanded at
37C (5% CO2) in RPMI 1640 medium supplemented with
8% human serum (Promocell) and recombinant IL-2
(150 U/ml) in the presence of irradiated BLCL cells and
allogeneic peripheral blood mononuclear cells (PBMC)
and PHA-L (1 lg/ml).
Plasmids
The full-length sequence of the HCMV-derived pp65 was
PCR ampliﬁed from the pcDNA6-pp65.35 plasmid (kind
gift of B. Plachter, Johannes Gutenberg-University, Mainz,
Germany) and cloned into the eukaryotic expression vector
pcDNA3.1/myc-HIS (version B). To generate Ub-pp65 and
FAT10-pp65 fusion proteins, the sequences encoding Ub
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123and FAT10 were PCR ampliﬁed from LPS-treated DC
cDNA and cloned in frame into the pcDNA3.1/pp65-myc-
HIS construct. A DNA fragment corresponding to the
FAT10 coding sequence was ampliﬁed from LPS-treated
DC cDNA by PCR using a forward primer encoding the
FLAG tag sequence. The PCR-ampliﬁed DNA was then
cloned into the pcDNA3.1/Zeo(?) expression vector
(Invitrogen) to generate a N-terminal FLAG-tagged version
of the FAT10 protein. Likewise, the sequence encoding the
amino acids 1–76 of human Ub was ampliﬁed by PCR
using forward primer encoding the epitope tag derived
from the inﬂuenza HA protein (YPYDVPDY) and cloned
into the pEGFPN3 plasmid (BD Clontech), so that a
HA-Ub-GFP fusion product can be synthesised following
transfection of mammalian cells. The full-length cDNA for
NUB1 and NUB1L was ampliﬁed by PCR from LPS-
treated DC using speciﬁc primers containing sequences
derived from the 50 and 30 portions, including their stop
codons and restriction enzyme sites compatible with
cloning into pcDNA3.1/myc-HIS expression vector.
In vitro transfection and western blotting
HeLa, HeLa A2?, HeLa A2?/IP and HEK293 cells were
transfected with 4 lg of each plasmid using Lipofectamine
2000 (Invitrogen). Sixteen hours after transfection, cells
were rapidly washed in ice-cold PBS and solubilised with a
NP40-based lysis buffer (50 mM Tris, 50 mM NaCl, 5 mM
MgCl2, 100 mM NEM, 10 lM MG132 and 0.1% NP40)
for 15 min on ice. The cell lysates were clariﬁed by cen-
trifugation (14,000g for 15 min). Protein concentration of
supernatants was determined using a BCA
TM protein assay
kit (Thermo Scientiﬁc), and 30 lg proteins were resolved
on SDS-PAGE and transfer to PVDF membranes (MilliQ).
Membranes were blocked for 30 min in PBS containing
5% milk followed by overnight incubation with primary
antibodies. After subsequent washings and incubation with
horseradish peroxidase-coupled secondary antibodies,
immunoblots were developed with the use of enhanced
chemoluminescence (ECL) (Amersham).
Immunoprecipitation
HeLa cells were transfected with an expression vector
encoding a HA-tagged Ub-GFP fusion protein (HA-Ub-
GFP) alone or in combination with plasmids encoding myc-
tagged versions of the pp65, Ub-pp65 or FAT10-pp65
constructs. After a 16-h transfection, whole-cell lysates
were made in lysis buffer (150 mM NaCl, 50 mM Tris, 1%
Triton
 X-100, 10 lM MG132, 100 mM NEM, pH 8.0)
and pre-cleared by centrifugation at[14,000g for 15 min
at 4C. The protein concentration in each cleared
supernatant was quantiﬁed using the BCA
TM protein assay
kit. Each sample was diluted in additional lysis buffer to
adjust each sample so that it has an equal concentration of
protein in 1 ml of total lysis buffer (typically 1 mg/ml).
Forty microlitre of myc-coated magnetic beads (lMACS
myc Kit; Miltenyi Biotec) were added to the supernatants,
incubated 1 h at 4C with rotation and loaded onto lMACS
columns (Miltenyi Biotec). Immunoprecipitates were
washed twice and eluted in loading buffer according to the
manufacturer’s instructions prior to SDS-PAGE and
western blotting with pp65 and HA antibodies.
RNA interference
RNA interference (RNAi) oligonucleotides speciﬁc for
PA28-a (L-012254-00), PA28-b (L-011370-01), LMP2
(L-006023-00), MECL1 (L-006019-00), LMP7 (L-006022-
00), Rpn10 (L-011365-00) and NUB1/NUB1L (L-019158-
00) were all purchased from Dharmacon. Non-targeting
control siRNA (D-001810-10) were also used in each
experiment and also obtained from Dharmacon. Brieﬂy,
HeLa A2? and/or HEK293 cells were seeded in six-well
plates and transiently transfected with non-targeting or
targeting siRNA at a ﬁnal concentration of 100 nM by
using the Xtremgene kit (Roche), according to the manu-
facturer’s protocol. The knockdown of the speciﬁed protein
was determined by western blotting using the appropriate
antibody. For DC transfection, 4 9 10
7 cells were resus-
pended in 100 ll Opti-MEM without red phenol
(Invitrogen) and transferred into a 4-mm electroporation
cuvette (Biorad) with 1,000 nmol siRNA duplex. The
electroporator (Genepulser; Biorad) used a square-wave
pulse of 500 V for 1 ms. Cells were then immediately
transferred into 4 ml of RPMI 1640 with 10% FCS, con-
taining GM-SCF and IL-4.
Antigen presentation assay
HeLa A2? or HeLa A2?/IP were transiently transfected
with pp65, FAT10-pp65 and Ub-pp65 and used as targets
cells for their potential to activate the production of IFN-c
by the pp65 CD8? T cell clone 61. Following 4 h of
transfection, target cells were serially diluted and then
co-cultured with a ﬁxed amount of T cells, resulting in
graded effector-to-target (E:T) ratio in a ﬁnal volume of
100 ll of RPMI 1640 supplemented with 10% FCS on
U-bottom 96-well plates. After 16 h of incubation, the
supernatants were collected and the IFN-c content was
determined using a commercially available human ELISA
kit according to the manufacturer’s instructions. The data
in the ﬁgures refer to the mean of two replicates. The SD
was below 5% of the mean.
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Whole cell lysates were used as pp65 antigen sources for
cross-presentation and prepared by four cycles of rapid
freeze/thaw lysis of HeLa cells transiently transfected with
pp65, Ub-pp65 or FAT10-pp65. Immature DC from HLA-
A2? donors were plated in duplicate on a 96-well plate at
50,000 cells per well and incubated for various periods of
time with the various whole cell lysates in the presence of
the pp65 CD8? T cell clone 61 at different responder-to-
stimulator ratio in a ﬁnal volume of 200 ll. Alternatively,
DC were used as unloaded or after being pulsed with 1 lM
of the pp65495–503 synthetic peptide NLVPMVATV in the
presence of LPS (1 lg/ml).
Statistical analysis
Student’s t test (one-tailed) was used for data analysis
when appropriate.
Results
FAT10 modiﬁcation of pp65 improves the presentation
of the HCMV pp65495–503 epitope
BecausebothUbandFAT10serveassignalsforproteasome-
dependent degradation, we compared their impact on MHC
classIpresentation.Tothisend,fusionproteinsconsistingof
the HCMV-derived pp65 antigen N-terminally tagged with
either Ub or FAT10 were expressed in HeLa A2? cells.
Monitoring the steady-state levels of the different pp65
constructs revealed that the expression level of FAT10-pp65
was strongly reduced whencompared to that of the untagged
pp65 (Fig. 1a). Importantly, the transcriptional activity of
thesetwoplasmidswasidentical(Fig.S1A).Furthermore,the
expression level of pp65 and FAT10-pp65 in the detergent-
insoluble fraction showed no signiﬁcant differences (Fig.
S1B), indicating that the cellular distribution of both of these
constructs was similar. Taken together, these data strongly
suggest that reduced signal for the FAT10-pp65 fusion pro-
tein observedinthedetergent-solublefractionreﬂectshigher
protein turnover. Detection of the Ub-pp65 fusion protein
revealed the expected efﬁcient initiation of poly-Ub chain
formationinvivo,asshownbyatypical8-kDaladderofhigh
molecular weight bands detected with the pp65 antibody. Of
the three bands detected, the lower one had the same
molecularsizeastheuntaggedpp65,indicatingthattheUbis
partially removed by de-ubiquitylating enzymes (DUB). Of
note, double conversion of glycine 75 and 76 to alanine and
valine at the isopeptidase site (UbAV-pp65) did not efﬁ-
ciently block the Ub cleavage from the fusion protein, as
determined by western blotting (Fig. S2A).
To analyze the ubiquitylation state of our different pp65
constructs, HeLa cells were transfected with HA-Ub-GFP
alone or in combination with pp65-myc, Ub-pp65-myc or
FAT10-pp65-myc for 16 h and were subsequently sub-
jected to a 6-h treatment with 10 lM MG-132. Following
incubation, the pp65 constructs were immunoprecipitated
using myc magnetic beads and analysed by immunoblotting
with anti-HA (against Ub) and anti-pp65 antibodies. As
shown in Fig. 1b, N-terminal tagging of pp65 with Ub
results in a strong poly-ubiquitylation of the Ub-pp65
fusion protein. A prolonged exposure of the western blot
with the anti-pp65 antibody reveals that at least four Ub
moieties are attached to the Ub-pp65 construct in these
cells (Fig. S3). In contrast, the untagged pp65 and the
FAT10-pp65 constructs were only slightly and similarly
ubiquitylated.
To test the impact of pp65, Ub-pp65 and FAT10-pp65
on the presentation of the pp65495–503 epitope in HeLa
A2? cells, pp65 epitope presentation was monitored using
a CD8? T cell clone (CTL clone 61) that speciﬁcally
recognises the immunodominant pp65495–503 epitope. To
prevent saturation levels of MHC class I/peptide com-
plexes, HeLa A2? cells were transfected with each
construct for only 4 h. As shown in Fig. 1c, in comparison
to the untagged pp65, the FAT10-pp65 fusion protein
enhanced antigen presentation approximately twofold and
activated the CTL clone 61 to a similar extent as that seen
with the Ub-pp65 fusion protein. Importantly, the improved
pp65495–503 presentation obtained with either Ub-pp65 or
UbAV-pp65 was substantially reduced when all the seven
lysine residues of the fused Ub moiety were changed into
arginine residues (UbK0-pp65) (Fig. S2B and S2C). These
data formally show that the enhanced pp65 CTL response
initiated by Ub-pp65 relies on the poly-ubiquitylation of its
N-terminal Ub.
The pp65495–509 epitope presentation derived
from FAT10-pp65 is less dependent on Rpn10
than that derived from Ub-pp65
The observation that the FAT10- and Ub-pp65 fusion
proteins similarly supported pp65495–503 epitope presenta-
tion raised the question concerning a putative receptor for
26S proteasome targeting. A major 26S proteasome
receptor for poly-ubiquitylated substrates is the Rpn10
subunit of the 19S regulatory particle, originally called S5a
[25, 26].
To determine whether Rpn10 may also serve as a
receptor for FAT10-modiﬁed substrates, we determined the
steady-state level of pp65, Ub-pp65 and FAT10-pp65 in
Rpn10-siRNA-silenced HeLa A2? cells. As illustrated
in Fig. 2a, RNAi treatment against Rpn10 for 96 h resulted
in an almost complete depletion of the Rpn10 subunit. The
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123Rpn10 knockdown was associated with a substantial sta-
bilisation of Ub-pp65 and FAT10-pp65 indicating that both
of these fusion proteins are targeted to Rpn10 for prote-
asomal degradation. The steady-state level of the untagged
pp65 in Rpn10-depeleted cells was also signiﬁcantly
affected which is in line with the observation that wild-type
pp65 undergoes poly-ubiquitylation in vivo. Nevertheless,
the stabilisation of FAT10-pp65 observed in the absence of
Rpn10 was less pronounced than that observed for the two
other pp65 constructs, suggesting a reduced afﬁnity of
FAT10-pp65 for Rpn10 or that Rpn10 is not the only
FAT10 interacting 26S proteasome subunit.
Next, we tested whether Rpn10 silencing may exert any
effect on the presentation of the pp65495–503 epitope arising
from our various pp65 constructs. As shown in Fig. 2b,
Rpn10 down-regulation resulted in a signiﬁcant impair-
ment of pp65495–503 epitope presentation deriving from the
untagged pp65 protein and the Ub-pp65 fusion protein.
Impairment of Rpn10 expression also affected the efﬁ-
ciency of pp65 epitope presentation exerted by the FAT10-
pp65 fusion protein. However, the observed decrease of
pp65 epitope presentation was less pronounced, which
appears to be in concordance with the reduced stabilization
of FAT10-pp65 upon Rpn10 deﬁciency demonstrated in
Fig. 2a. These data not only reveal that Rpn10 is involved
in the proteasomal degradation of pp65 and Ub-pp65 but
also suggest that Rpn10 can act as receptor for FAT10-
modiﬁed substrates.
FAT10-pp65 processing is not controlled
by i-proteasomes and/or PA28
In many cases, i-proteasomes or the proteasome activator
PA28 positively inﬂuence presentation of epitopes arising
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Fig. 1 Increasedreactivityofthepp65495–503-speciﬁcCTLclone61by
HeLaA2?cellstransientlyexpressingeitherUb-pp65orFAT10-pp65.
a HeLa A2? cells were transfected with the various plasmids for 24 h
and whole cell extracts were mixed with sample buffer, followed by
SDS-PAGE separation and western blotting with pp65, Ubiquitin
(FK2) and FAT10 antibodies. Loading control was ensured by probing
themembranewiththeanti-b-actinmAb.bHeLacellsweretransfected
with HA-Ub-GFP alone or in combination with pp65-myc, Ub-pp65-
myc or FAT10-pp65-myc for 16 h after which they were subjected to a
6-h treatment with 10 lM MG-132. Following incubation, cells were
harvested and subjected to immunoprecipitation with myc-coated
magneticbeadsandwesternblotanalysiswithanti-HA(againstUb)and
anti-pp65 mAb, as indicated. Loading control in this experiment was
ensured by monitoring the expression levels of the GFP protein, which
is immediately cleaved from the HA-Ub-GFP fusion product by
hydrolasesshortlyafter synthesis.cFollowinga4-htransfection,HeLa
A2?cellsexpressingpp65,Ub-pp65orFAT10-pp65werewashedand
added to the pp65 CTL clone 61 recognising the HLA-A2-restricted
pp65495–503 epitope at various E:T ratio for 16 h. The activation of the
CTL clone 61 was assessed by measuring IFNc content in the
supernatant by ELISA (*p\0.01, compared with untagged pp65,
n = 3)
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123from poly-ubiquitylated antigens [27, 28]. Therefore, we
next studied the role of i-proteasomes in the processing of
FAT10-pp65 in HeLa A2?/IP cells that predominantly
express i-proteasomes [24]. As shown in Fig. 3a, expres-
sion of either pp65 or Ub-pp65 in HeLa A2?/IP resulted in
improved antigen presentation of the pp65495–503 epitope,
when compared to HeLa A2? control target cells that
predominantly express s-proteasomes. In striking contrast,
the presence of i-proteasomes exerted no effect on the
efﬁciency of the FAT10-mediated pp65 epitope presenta-
tion, indicating that the molecular prerequisites for FAT10-
dependent antigen processing differ from those of the
Ub-dependent pathway.
We next studied the effects of PA28 on the presentation
of the pp65495–503 epitope derived from the FAT10-pp65
fusion protein. To deprive the target cells of PA28, both
PA28-a and PA28-b were silenced by siRNA. Cells
transfected without siRNA or non-targeting siRNA oligo-
nucleotides (control siRNA) were used as controls.
Following successful down-regulation of PA28 (Fig. 3c),
HeLa A2? cells were transfected with pp65, Ub-pp65 or
FAT10-pp65 and the pp65495–503 CTL response was
monitored by IFN-c release assays. As shown in Fig. 3b,
the presentation of the pp65495–503 epitope liberated from
untagged pp65 or the FAT10-pp65 fusion remained largely
unaffected in PA28-depeleted HeLa A2? cells. In contrast,
the presentation of the pp65495–503 epitope derived from the
Ub-pp65 fusion protein was considerably reduced follow-
ing down-regulation of PA28 expression in HeLa A2?
cells. Taken together, these data demonstrate that neither
i-proteasomes nor PA28 signiﬁcantly inﬂuence the pro-
cessing of FAT10-modiﬁed substrates for MHC class I
presentation. This conclusion ﬁnds further support by the
observation that the accumulation of FAT10-modiﬁed
proteins following a combined treatment of TNF-a and
IFN-c is not altered in i-proteasome- or PA28-depleted
HEK293 cells (Fig. 4).
NUB1 and its splicing variant NUB1L speciﬁcally
regulate the pp65495–503 presentation arising
from FAT10-pp65
Both the Ub-binding proteins NUB1 and its splicing variant
NUB1L have been shown to accelerate the degradation of
FAT10 [29] and thus appear to be important regulators of
both poly-Ub- and FAT10-dependent protein degradation.
We therefore next investigated the effects of NUB1 and
NUB1L on the steady-state levels of pp65, Ub-pp65 and
FAT10-pp65. Untagged versions of NUB1 or NUB1L were
co-expressed in HeLa A2? cells together with pp65,
Ub-pp65orFAT10-pp65andtheirrelativeexpressionlevels
were monitored by western blotting using a monoclonal
FAT10-pp65
+ - - ----pp65 B A
2000
3000
4000
3000
4000
5000
6000
7000
8000
Rpn10 siRNA
Control siRNA
No siRNA
Ub-pp65
-
-
+
-
-
-
+
-
-
-
+
-
-
-
-
-
-
+
-
+
+ +
-
+
-
-
+
+
-
-
-
+
-
-
+
+
-
-
+
-
+
-
+
-
-
+
-
Ub-pp65 pp65
**
** **
0
1000
0
1000
2000
5000
-
γ
(
p
g
/
m
l
)
I
F
N
-
γ
(
p
g
/
m
l
)
I
F
N
1
:
1
2
:
1
4
:
1
8
:
1
1
6
:
1
3
2
:
1
E:T ratio
1
:
1
2
:
1
4
:
1
8
:
1
1
6
:
1
3
2
:
1
E:T ratio
72
55
pp65 (short exp.)
pp65 (long exp.) 72
55
0
1000
2000
3000
4000
Rpn10
β-actin
I
F
N
-
γ
(
p
g
/
m
l
)
FAT10-pp65
No siRNA
Control siRNA
Rpn10 siRNA
43
43
*
*
1
:
1
2
:
1
4
:
1
8
:
1
1
6
:
1
3
2
:
1
E:T ratio
Fig. 2 Rpn10 knockdown in HeLa A2? cells leads to impaired
presentation of the pp65495–503 epitope generated from pp65, Ub-pp65
or FAT10-pp65 proteins. a The role of Rpn10 in the turn-over of the
pp65, Ub-pp65 or FAT10-pp65 substrates was examined by treating
HeLa A2? cells with either control or Rpn10 siRNA for 4 days
followed by a subsequent transfection with the pp65, Ub-pp65 or
FAT10-pp65 plasmids for 24 h, as indicated. The gene silencing
efﬁciency for Rpn10 was determined by western blotting using a
monoclonal antibody against Rpn10. The inﬂuence of Rpn10
depletion on the steady-state level of pp65, Ub-pp65 and FAT10-
pp65 was examined by western blotting using the anti-pp65 antibody.
b Rpn10-depleted HeLa A2? cells were transfected with the pp65,
Ub-pp65 or FAT10-pp65 plasmids for 4 h and used as target cells in a
16-h co-culture against the CTL clone 61. Controls in this CTL assay
consist in the use of HeLa A2? cells expressing pp65, Ub-pp65 or
FAT10-pp65 which have been treated with non-targeting siRNA
(control siRNA) or left untreated (no siRNA). The activation of the
CTL clone 61 was assessed by measuring the IFN-c content in the
supernatant by ELISA. (*p\0.01 and **p\0.005, compared to
untreated cells or cells treated with control siRNA, n = 2)
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123anti-pp65 antibody. In accordance with previous studies
[30], both NUB1 and NUB1L signiﬁcantly enhanced the
degradationrateoftheFAT10-pp65fusionprotein(Fig. 5a).
However, only NUB1L signiﬁcantly accelerated the turn-
over of the Ub-pp65 fusion protein, suggesting that NUB1
and NUB1L differ intheir ability to shuttle Ubsubstrates for
proteasomal degradation. Coincidently, over-expression of
either NUB1 or NUB1L resulted in substantially improved
presentation of the FAT10 derived pp65495–503 antigenic
peptide (Fig. 5b). Likewise, over-expression of NUB1L
together with Ub-pp65 was accompanied by an increased
activation of the pp65495–503 CD8? T-cell clone. By con-
trast, the over-expression of either NUB1 or NUB1L had no
substantial effect on the pp65495–503 antigen presentation
arising from the untagged pp65 (Fig. 5b).
To test and compare the impact of pp65, Ub-pp65 and
FAT10-pp65 on cross-presentation, monocyte-derived DC
were loaded with whole cell lysates containing pp65,
Ub-pp65 or FAT10-pp65, co-cultured with the pp65 CTL
clone 61 in the presence of LPS, and IFN-c release was
assayed, as previously described [14, 31]. As shown in
Fig. 6a, DC fed with either FAT10-pp65 or Ub-pp65
proteins elicited signiﬁcant responses following 12 h of
co-culture which almost equalled those measured with the
synthetic 9-mer pp65 peptide, but which were nearly
twofold greater than those observed with the untagged
pp65 protein. Interestingly, the enhancement of pp65
cross-presentation elicited by the Ub-pp65 was already
visible after 4 h, while enhancement of the immune
response elicited by the FAT10-pp65 fusion protein
became detectable after 12 h of co-culture. Importantly,
the early pp65 CTL response observed with Ub-pp65 was
abrogated when using preﬁxed DC (Fig. S4), indicating
that the pp65 cross-presentation initiated in the ﬁrst 4 h of
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Fig. 3 The presentation of the pp65495–503 antigenic peptide arising
from the FAT10-pp65 fusion protein is not inﬂuenced by i-protea-
somes and/or PA28. a The role of i-proteasomes in the presentation of
the pp65495–503 antigenic peptide arising from the pp65, Ub-pp65 and
FAT10-pp65 fusion proteins was assessed in a 16-h CTL assay using
targets cells consisting of HeLa A2? cells having dominantly
s-proteasomes or HeLa A2?/IP cells over-expressing the three
inducible subunits LMP2, MECL1 and LMP7, as indicated
(*p\0.01, compared with HeLa A2? having predominantly a
s-proteasome, n = 3). b HeLa A2? cells were left untreated (no
siRNA) or treated with non-targeting siRNA (control siRNA)o ra
combination of siRNA speciﬁc for PA28-a and PA28-b. After 48 h,
these cells were subjected to a short 4-h transfection with the pp65,
Ub-pp65 and FAT10-pp65 plasmids and used as target cells in a CTL
assay for monitoring the presentation of the pp65495–503 peptide, as
described in a (**p\0.005, compared with untreated cells or cells
treated with control siRNA, n = 3). c The content of HeLa A2? for
PA28 was analysed by western blotting using an antibody speciﬁc for
PA28-b. Anti-b-actin antibody was used to ensure equal protein
loading
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123co-culture requires processing and is not due to peptide
transfer from the antigen-donor cells to the DC cell sur-
face HLA-A2? molecules.
Because of the observation that both NUB1 and NUB1L
accelerate the degradation of FAT10-pp65, we next aimed
to estimate the transcription level of both of these proteins
in maturing DC following LPS stimulation using RT-PCR.
As shown in Fig. 6b, NUB1 and, to a much lesser extent,
NUB1L were induced in LPS-treated DC from 4 h of
stimulation. However, we were unable to determine whe-
ther both abundant splice variants of the two NUB1
isoforms were translated because they were indistinguish-
able in western blot analyses (Fig. 6c). To address the role
of the increased expression of NUB1 and NUB1L in cross-
presentation, day-5 immature DC were electoporated with
siRNA speciﬁc for NUB1/NUB1L for 24 h prior to a
subsequent stimulation with LPS, which resulted in a
strong impairment of NUB1/NUB1L up-regulation
(Fig. 6d). Strikingly, the pp65495–503 cross-presentation
arising from DC fed with pp65, Ub-pp65 or FAT10-pp65
was reduced by about 20% in NUB1/NUB1L-depleted DC
(Fig. 6e), demonstrating the contribution of NUB1/NUB1L
to proteasome-dependent cross-presentation of the
pp65495–503 epitope.
Discussion
FAT10 is the only UBL so far known that shares with Ub
the capacity of targeting substrates for proteasomal
breakdown. However, very little is known about its func-
tion and nothing is known about its ability to support the
generation of peptides suitable for MHC class I presenta-
tion. Here, we demonstrate that FAT10 modiﬁcation of the
HCMV-derived antigen pp65 (FAT10-pp65) enhances the
presentation of the HLA-A2-restricted pp65495–509 anti-
genic peptide (Fig. 1c) and provide evidence that FAT10-
pp65 differs from Ub-modiﬁed pp65 in using the protea-
some machinery. The pp65495–503 presentation obtained
with Ub-pp65 is improved by approximately 50%. This is
less than originally observed by Townsend and colleagues
with the NP365–370 peptide using a Ub-Arg-NP fusion
protein (N-end rule) [1]. However, this discrepancy can be
explained by the fact that, in contrast to the pp65495–503
presentation, the NP365–370 presentation is defective and, as
such, increases much more dramatically following N-ter-
minal Ub fusion.
While this paper was under revision, an interesting study
of Buchsbaum and co-workers reported that the increased
degradation rate of a FAT10-GFP fusion protein is facili-
tated by poly-ubiquitylation [32]. Our data show that our
FAT10-pp65 fusion protein is not more poly-ubiquitylated
than the untagged pp65 (Fig. 1c; Fig. S3), suggesting that
the accelerated degradation of this construct cannot be
attributed to its enhanced poly-ubiquitylation state. Our
results do not formally exclude a possible involvement of
the Ub-conjugation system in the regulation of the break-
down of FAT10-pp65. Nevertheless, our results would still
imply that the processing of a substrate bearing simulta-
neously FAT10 and Ub differs from that of Ub-tagged or
posttranslationally Ub-modiﬁed proteins.
Also, the FAT10-pp65 fusion protein expressed in HeLa
cells improved cross-presentation of the pp65 epitope by
LPS-stimulated DC demonstrating that FAT10 modiﬁca-
tion provides an alternative signal for efﬁcient antigen
processing and subsequent MHC class I presentation.
Induction of FAT10 synthesis requires IFN-c and TNF-a
[22], which also trigger the synthesis of i-proteasomes and
the proteasome activator PA28. Despite this, and in striking
contrast to poly-ubiquitylated pp65, the FAT10-dependent
pp65 epitope presentation was already most efﬁcient in the
presence of s-proteasomes and was not further enhanced by
i-proteasomes or PA28 (Fig. 3a, b). These data suggest that
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Fig. 4 The expression pattern of FAT10-protein conjugates in
response to TNF-a and IFN-c is not altered by depletion of either
i-proteasomes or PA28. The role of PA28 and the i-proteasome in the
steady-state level of the accumulated FAT10-modiﬁed substrates was
assessed by treating HEK293 cells with siRNA speciﬁc for PA28-a/b
or for the three inducible proteasomal subunits LMP2/MECL1/LMP7
(IP), respectively. After 24 h, cells were treated with a combined
treatment of TNF-a and IFN-c or left untreated prior to a subsequent
24-h transfection with the ﬂag-tagged FAT10 plasmid. The membrane
shown was subjected to western blot analysis using antibodies against
FAT10, PA28-a, PA28-b, LMP2, MECL1 and LMP7, as indicated.
Equal loading was determined by using anti-b-actin mAb
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123the degradation of the FAT10- and Ub-protein conjugates
are governed by different molecular mechanisms. One
possible explanation for this surprising result may be that
FAT-10- and Ub-modiﬁed proteins interact with the 26S
proteasome in different ways. Interestingly, our experi-
ments show that both FAT10-pp65 and Ub-pp65 share the
19S regulator subunit Rpn10 (Fig. 2a), known to bind poly-
Ub-chains as interaction partner [25, 26]. However, siRNA
experiments also revealed that, while Rpn10 deﬁciency
exerts profound negative effects on the presentation of the
pp65 epitope derived from Ub-pp65, the effect on the
FAT10-pp65-derived epitope is considerably less pro-
nounced (Fig. 2b). In light of the extremely efﬁcient
proteasome-dependent turnover of FAT10-pp65, this may
indicate that FAT10 binds Rpn10 less efﬁciently and/or
that Rpn10 is not the only and not the decisive interaction
partner of FAT10 modiﬁed proteins within the 26S pro-
teasome complex.
So far, NUB1L and its natural splicing variant NUB1
(which has a deletion of 14 amino acids) had been the only
proteins identiﬁed to ferry FAT10 for proteasome-depen-
dent degradation [22, 30]. Our data further support a role
for both NUB1 and NUB1L in facilitating the breakdown
of FAT10-modiﬁed substrates, as evidenced by decreased
steady-state levels of the FAT10-pp65 fusion protein in
cells over-expressing NUB1 or NUB1L (Fig. 5a). Impor-
tantly, the accelerated degradation of FAT10-pp65 by
NUB1 or NUB1L was accompanied by a marked increase
of the pp65495–503 CTL response (Fig. 5b). However, our
experiments rule out an entirely overlapping function of
NUB1 and NUB1L because only NUB1L was found to
enhance the turnover of the Ub-pp65 fusion (Fig. 5a).
Thus, unlike NUB1 (which appears FAT10-speciﬁc),
NUB1L seems to be positioned at the intersection of the Ub
and FAT10 pathways, suggesting a model in which the
accelerated disposal of Ub-modiﬁed proteins by NUB1L is
connected to an increased supply of antigenic peptides for
MHC class I presentation.
The optimal form of the antigenic source for effective
cross-priming is still a matter of debate, ranging from
stable antigens as being a favourable source for cross-
presentation [33–35] to unstable proteins, including
defective ribosomal products (DriPs), being more effective
than mature proteins for stimulating cross-priming [36, 37].
Our data show that both Ub and FAT10 fusion proteins
serving as vehicles for pp65 delivery into DC were by far
superior in activating CTL to the untagged pp65 (Fig. 6a).
This data would support the notion that short-lived proteins
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Fig. 5 NUB1 and NUB1L accelerate the protein turnover of FAT10-
pp65 which results in improved presentation of the pp65495–509
antigenic peptide in HeLa A2? cells. a Untagged versions of NUB1
and NUB1L were co-expressed together with pp65, Ub-pp65 or
FAT10-pp65 in HeLa A2? cells and their respective inﬂuence on the
steady-state level of each pp65 antigenic variant was determined by
western-blot using an anti-pp65 monoclonal antibody. The over-
expression of NUB1 and NUB1L was checked by probing the
membrane with a polyclonal antibody recognising both NUB1 and
NUB1L (equal protein loading was ensured by using the anti-b-actin
mAb). b The effects of NUB1 and NUB1L over-expression were also
tested for the presentation of the pp65495–503 peptide emerging from
pp65, Ub-pp65 or FAT10-pp65. HeLa A2? cells were transfected
with either the pcDNA3.1 empty vector (mock), NUB1 or NUB1L for
24 h prior to a subsequent transient transfection with the pp65,
Ub-pp65 or FAT10-pp65 constructs for 4 h. Cells co-expressing
NUB1 or NUB1L and the various pp65 antigenic forms were
subsequently tested for their capacity to present the pp65495–503
antigenic peptide using the CTL clone 61 in a 16-h IFN-c release
assay (*p\0.01, compared to HeLa A2? cells transfected with the
pcDNA3.1 empty vector, n = 2)
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123are better cross-presented than the stable ones. Interest-
ingly, there exist kinetic differences in enhancing cross-
presentation, with cross-presentation from the FAT10-pp65
fusion being considerably lower during the ﬁrst 4 h of the
assay than that observed with Ub-pp65. However, Ub-pp65
and FAT10-pp65 exerted almost identical cross-presenta-
tion efﬁciency after 12 h of co-culture.
Interestingly, NUB1 and, to a lesser extent, NUB1L are
induced during the course of LPS-induced DC maturation.
The fact that at the transcriptional level the NUB1/NUB1L
ratio was close to 10 (Fig. 6b, c), seems to suggest that
NUB1 is the major isoform in mature DC silencing of
NUB1/NUB1L expression and was accompanied by a slight
but signiﬁcant decrease of the pp65 cross-presentation levels
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Fig. 6 Both FAT10 and Ub facilitate cross-presentation of the
pp65495–503 epitope by DC when fused to the N-terminus of the
HCMV-derived pp65 protein. a Immature HLA-A2? DC were fed
with pp65, Ub-pp65 or FAT10-pp65 necrotic HeLa cells at a ratio at 2
per DC and simultaneously exposed to LPS (1 lg/ml) to induce
maturation. The ability of pp65-, Ub-pp65- and FAT10-pp65-pulsed
DC to stimulate the CTL clone 61 was tested in a 4- or 12-h IFN-c
release assay, as indicated. Internal controls consist in DC loaded
with 1 lm of the 9-mer synthetic pp65495–503 peptide (*p\0.01,
compared to DC loaded with untagged pp65, n = 2). b RT-PCR
analysis of NUB1 and NUB1L transcripts in LPS-treated DC
following various periods of time. The ampliﬁed RT-PCR products
NUB1 and NUB1L were separated on 2% agarose gels and visualised
by ethidium bromide. Electrophoresis of the PCR products showed
NUB1 (222 bp) band and a larger band corresponding to NUB1L
(256 bp). PCR using GAPDH showed similar ampliﬁcation levels
among the samples tested. c Time-course induction of NUB1 and
NUB1L in DC following LPS stimulation as assessed by western-
blotting. Day 5-immature DC were treated with 1 lg/ml LPS for
various periods of time, as indicated. Thirty micrograms of total
cellular proteins were loaded in each lane and resolved 12% SDS-
PAGE gel followed by western blotting with a polyclonal antibody
speciﬁc for both NUB1 and NUB1L. Equal amounts of proteins was
ensured using GAPDH antibody. d Western blot analysis for NUB1/
NUB1L in untreated DC or DC treated with control siRNA or NUB1/
NUB1L-speciﬁc siRNA, as indicated. e HLA-A2? DC with a
knockdown of NUB1/NUB1L were loaded with 1 lM of the
pp65495–503 synthetic peptide or cell-associated pp65, Ub-pp65 and
FAT10-pp65 and subsequently cultured with the CTL clone 61 at a
E:T ratio of 1:1 in the presence of LPS (1 lg/ml). Cross-presentation
of the pp65495–503 peptide was assessed by measuring the IFN-c
content in the supernatant following 12 h of co-culture (*p\0.01,
compared to DC treated with control siRNA, n = 2)
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123by DC (Fig. 6e). Surprisingly, however, impairment was
not restricted to DC loaded with FAT10-pp65 but was also
observed to a similar extent with DC loaded with either
untagged pp65 or Ub-pp65. This appears to contrast with
the observation that NUB1 and/or NUB1L can only
enhance MHC class I presentation of FAT10 substrates.
However, given the sensitivity of the assay, the low
amounts of NUB1L expressed during DC maturation are
probably sufﬁcient to inﬂuence processing of the pp65
epitope derived from untagged pp65 and Ub-pp65. Alter-
natively, the sensibility of pp65 and Ub-pp65 to NUB1/
NUB1L down-regulation may indicate that both forms of
the pp65 antigen undergo FAT10 modiﬁcation within DC
prior to proteasomal degradation for cross-presentation.
Proteasome-dependent cross-presentation was previously
estimated to only contribute to total cross-presentation to
approximately 30% [38]. Keeping this in mind, the
observed inhibitory effect on cross-presentation of about
20% exerted through the knockdown of NUB1/NUB1L
support the central role of the two proteasomal adapter
proteins in antigen cross-presentation.
Collectively, our ﬁndings outline the FAT10-NUB1/
NUB1L-Rpn10 axis as a novel route for MHC class I
antigen direct presentation and DC-based cross-presenta-
tion. Considering the strongly delayed expression of
FAT10 upon cytokine stimulation, the existence of this
new route may allow presentation of antigenic peptides that
would not be generated in adequate amounts by the clas-
sical Ub-conjugation pathway. Nevertheless, the
contribution of each pathway to antigen presentation is
difﬁcult to assess. The moderate or absent phenotype
exhibited by FAT10-deﬁcient mice [19] suggests that the
FAT10-conjugation pathway may not be a privileged and/
or the predominantly used pathway for MHC class I pre-
sentation. This hypothesis is further supported by the
observation that FAT10 is not expressed in cells under
normal conditions. It is instead conceivable that the
FAT10-conjugation machinery represents a complemen-
tary pathway which is used when Ub availability becomes
a rate-limiting factor. Interestingly, FAT10 is up-regulated
at the transcriptional level by cytokines (i.e., TNF-a and/or
IFN-c), which are also thought to deplete the pool of free
Ub by increasing the formation of Ub-protein conjugates in
immune cells [14, 39] as well as in non-immune cells [24].
Therefore, the role of the FAT10-dependent degradation
machinery may be to support an overloaded Ub pathway in
the removal of damaged proteins in later phases of stimu-
lation. For the same reason, this route may be up-regulated
in some pathological conditions such as viral infections
and/or tumours, and may explain the observation that
FAT10 is over-expressed in tumours exhibiting an alter-
ation of the Ub-conjugation system such as in gastric
cancer [17, 40]. Taken together, these data highlight the
FAT10-dependent degradation machinery as a distinct
MHC class I antigen processing pathway and suggest new
avenues for FAT10-based immunotherapy in viral infec-
tions as well as in anti-tumour vaccinations.
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